<DOC>
	<DOCNO>NCT00830518</DOCNO>
	<brief_summary>This open-label , multicenter , phase 2 study MLN8237 patient acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>A Phase 2 Trial MLN8237 Adult Patients With Acute Myelogenous Leukemia High-Grade Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion : 1 . Male female patient 18 year old 2 . Eligible diagnosis : Acute myelogenous leukemia ( except APL ) &gt; 10 % bone marrow peripheral blood blast ; fail achieve CR relapse prior therapy , candidate potentially curative treatment . Untreated patient &gt; 60 eligible candidate standard induction . Highgrade MDS , define follow feature : IPSS Intermediate2 High Risk ; &gt; 10 % blast bone marrow examination ; treatment failure , candidate , standard therapy include demethylating agent , eg azacytidine decitabine . 3 . Eastern Cooperative Oncology Group perf . status 02 4 . Female patient : Postmenopausal least one year Surgically sterile , If childbearing potential , agree practice two effective method contraception abstain heterosexual intercourse . 5 . Male patient : Practice effective barrier contraception one month last dose study drug , Abstain heterosexual intercourse . 6 . Voluntary write consent 7 . Patients hydroxyurea may include 1 . Pregnant lactating female 2 . Known human immunodeficiency virus ( HIV ) positive AIDSrelated illness 3 . Serious medical psychiatric illness could , investigator 's opinion , potentially interfere protocol completion 4 . Total bilirubin &gt; 1.5 × upper limit normal ( ULN ) 5 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 × ULN . AST , ALT may elevate 5 x ULN reasonably ascribe underlying hematological disorder . 6 . Calculated creatinine clearance &lt; 30 mL/minute 7 . Antineoplastic radiotherapy within 14 day precede first dose 8 . Myocardial infarction within 6 month enrollment current history New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia 9 . Major surgery 14 day prior first dose 10 . Clinically uncontrolled central nervous system ( CNS ) involvement . 11 . Inability swallow capsule 12 . History uncontrolled sleep apnea condition result excessive daytime sleepiness , chronic lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>